A VISIONaerie® approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with glaucoma, dry eye, retinal diseases and other diseases of the eye
News HighlightsAerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 (TRPM8 ... Santen and Aerie Conclude Exclusive License Agreement for Rhopressa® and R... Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug ...
Oct 30, 4:00 PM ET
52 - WEEK LOW/HIGH